Colorectal cancer treatment is undergoing a fundamental shift toward biomarker-driven, personalized therapy, according to recent findings presented at the ESMO GI 2026 conference. Clinical data from trials such as KRYSTAL-10, CAPRI-2 GOIM, ATOMIC, and BREAKWATER suggest that while targeted therapies are transforming outcomes, traditional chemotherapy remains a critical component of successful treatment regimens.
Precision Oncology and the Role of KRAS G12C Inhibition
The KRYSTAL-10 trial evaluated adagrasib plus cetuximab as a second-line treatment for patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC). Although the study did not meet its primary endpoints for progression-free survival (PFS) or overall survival (OS), the combination demonstrated an objective response rate of 47%, significantly higher than the 16% seen with chemotherapy.
Davide Ciardiello, MD, PhD, of the European Institute of Oncology, notes that results should be interpreted with caution. The chemotherapy control arm performed better than historical benchmarks, and a high proportion of control-arm patients later received KRAS G12C inhibitors. When adjusting for these confounders in post hoc modeling, the targeted combination showed a statistically significant survival benefit. The future of this treatment likely involves integrating KRAS G12C inhibitors with both anti-EGFR antibodies and chemotherapy to improve patient outcomes.
Liquid Biopsy and Cetuximab Sequencing
The CAPRI-2 GOIM study examined whether continuing cetuximab after disease progression is viable for patients with RAS and BRAF V600E wild-type, microsatellite-stable mCRC. By using liquid biopsies to monitor circulating tumor DNA (ctDNA), researchers identified "negative hyperselected" patients—those without resistance-associated alterations across a 14-gene panel.
These patients experienced significantly longer progression-free survival when continuing cetuximab compared to those with resistance markers. Davide Ciardiello suggests this approach is a promising proof of concept for maintaining anti-EGFR blockade by switching the chemotherapy backbone. The ongoing CAPRI-3 GOIM study is now testing this by randomizing patients to chemotherapy plus cetuximab or bevacizumab after first-line progression.
Did you know? The CAPRI-2 GOIM study used a 14-gene panel to identify patients without resistance-associated alterations, defined as "negative hyperselected" patients.
Chemotherapy Duration in Adjuvant Settings
The ATOMIC trial explored the impact of treatment duration on stage III deficient mismatch repair (dMMR) colon cancer. By analyzing patients who received six months of adjuvant mFOLFOX6 with or without atezolizumab, researchers found that disease-free survival benefits were most pronounced in patients who completed more than six cycles of chemotherapy.
Davide Ciardiello emphasizes that for localized colon cancer, chemotherapy retains a vital role. While early discontinuation of oxaliplatin is sometimes necessary due to toxicity, the ATOMIC data suggest that at least six cycles of oxaliplatin-based therapy are required when combined with immunotherapy to maximize survival benefits.
Molecular Heterogeneity in BRAF V600E-Mutant mCRC
The BREAKWATER study provided a deep dive into the molecular correlates of response for BRAF V600E-mutant mCRC. Translational analysis revealed that the triplet combination of encorafenib, cetuximab, and mFOLFOX6 is effective regardless of specific genomic alterations like APC or RNF43 status.
Adding mFOLFOX6 to the targeted regimen also reduced the emergence of resistance-associated alterations compared to targeted therapy alone. Davide Ciardiello advocates for using induction chemotherapy followed by maintenance with fluorouracil, encorafenib, and cetuximab. This strategy aims to curb the development of resistance that often occurs when using targeted agents in isolation.
Frequently Asked Questions
Can chemotherapy be discontinued early in adjuvant treatment?
According to analysis from the ATOMIC study, at least six cycles of oxaliplatin-based therapy are recommended when combined with immunotherapy to ensure optimal disease-free survival.
What is the "negative hyperselected" strategy in colorectal cancer?
This strategy, investigated in the CAPRI-2 GOIM trial, uses liquid biopsies to identify patients who lack resistance-associated genetic mutations, allowing them to potentially continue anti-EGFR therapy after first-line progression.
Why is chemotherapy still used with targeted therapy?
Data from the BREAKWATER and KRYSTAL-10 studies indicate that chemotherapy helps reduce the emergence of resistance-associated alterations and provides a baseline for efficacy in molecularly selected tumors.
What role does ctDNA play in modern cancer treatment?
ctDNA profiling enables clinicians to monitor tumor evolution in real-time, helping to guide treatment sequencing and decisions on whether to continue or switch targeted agents.
For more information on the evolving standards of care, explore our latest coverage of ctDNA blood tests in colorectal cancer screening.
Related reading